14 studies found for:    ch14.18
Show Display Options
Rank Status Study
1 Completed ch14.18/CHO Bridging Study
Condition: Neuroblastoma
Intervention: Drug: ch14.18/CHO
2 Recruiting Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)
Condition: Neuroblastoma
Interventions: Drug: ch14.18/CHO;   Drug: Aldesleukin;   Drug: Isotretinoin
3 Active, not recruiting Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Biological: aldesleukin;   Other: diagnostic laboratory biomarker analysis;   Biological: sargramostim;   Biological: monoclonal antibody Ch14.18;   Drug: isotretinoin
4 Recruiting Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Condition: Recurrent Neuroblastoma
Interventions: Drug: temozolomide;   Drug: irinotecan hydrochloride;   Drug: temsirolimus;   Biological: dinutuximab;   Biological: sargramostim;   Other: laboratory biomarker analysis
5 Recruiting Isotretinoin With or Without Monoclonal Antibody Ch14.18, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: isotretinoin;   Biological: sargramostim;   Biological: dinutuximab;   Biological: aldesleukin;   Other: laboratory biomarker analysis;   Other: quality-of-life assessment;   Other: pharmacological study
6 Not yet recruiting Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Localized Resectable Neuroblastoma;   Localized Unresectable Neuroblastoma;   Neurotoxicity;   Pain;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: cytology specimen collection procedure;   Other: pharmacological study
7 Completed Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Recurrent Neuroblastoma;   Regional Neuroblastoma
Interventions: Biological: monoclonal antibody Ch14.18;   Drug: isotretinoin;   Biological: aldesleukin;   Biological: sargramostim
8 Completed ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: ch14.18 -NCI;   Biological: ch14.18-UTC;   Biological: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF);   Biological: Aldesleukin (IL-2);   Drug: Isotretinoin
9 Recruiting Lenalidomide and Monoclonal Antibody With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
Conditions: Disseminated Neuroblastoma;   Localized Unresectable Neuroblastoma;   Recurrent Neuroblastoma;   Regional Neuroblastoma;   Stage 4S Neuroblastoma
Interventions: Drug: lenalidomide;   Biological: dinutuximab;   Drug: isotretinoin;   Other: pharmacological study;   Other: laboratory biomarker analysis
10 Recruiting High Risk Neuroblastoma Study 1 (1.5) of SIOP-Europe (SIOPEN)
Condition: Neuroblastoma
Interventions: Drug: Vincristine;   Drug: Aldesleukin;   Drug: ch14.18/CHO;   Drug: Carboplatin;   Drug: Etoposide;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: G-CSF;   Drug: Busulfan i.v.;   Drug: Melphalan
11 Not yet recruiting Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma
Conditions: Neuroblastoma;   Neoplasm, Residual;   Effects of Immunotherapy
Intervention: Drug: Dinutuximab. Immunotherapy
12 Unknown  Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma
Condition: Neuroblastoma
Interventions: Biological: filgrastim;   Biological: monoclonal antibody Ch14.18;   Drug: busulfan;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: isotretinoin;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: bone marrow ablation with stem cell support;   Procedure: conventional surgery;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
13 Recruiting Therapy for Children With Advanced Stage Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: cyclophosphamide;   Drug: topotecan;   Biological: hu14.18K322A;   Procedure: peripheral blood stem cell harvest;   Procedure: surgical resection;   Drug: cisplatin;   Drug: etoposide;   Drug: doxorubicin;   Drug: vincristine;   Drug: busulfan;   Drug: melphalan;   Biological: peripheral blood stem cell transplantation;   Biological: natural killer cell infusion;   Radiation: radiation therapy;   Biological: GM-CSF;   Biological: G-CSF;   Drug: mesna;   Drug: levetiracetam;   Biological: interleukin-2;   Drug: Isotretinoin
14 Recruiting High Dose Chemotherapy and Autologous Transplant for Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Carboplatin;   Biological: Autologous stem cell infusion;   Biological: Granulocyte colony stimulating factor;   Radiation: Radiation therapy;   Drug: Isotretinoin (13-cis-retinoic acid);   Drug: Melphalan;   Drug: Etoposide

Indicates status has not been verified in more than two years